Jean-William Dupuy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jean-William Dupuy has a total of 787 co-authors. Here are the top co-authors by number of shared publications:
- Anne-Aurélie Raymond
Univ.Bordeaux, Inserm UMR1312 BoRdeaux Institute of onCology (BRIC)
20 shared publications - Frédéric Saltel
University of Bordeaux, INSERM, UMR1312, BRIC, BoRdeaux Institute of onCology
19 shared publications Marc Bonneu
Bordeaux University, 146 rue Léo Saignat, 33000, Bordeaux, France
12 shared publications- Sylvaine Di Tommaso
Univ.Bordeaux, Inserm UMR1312 BoRdeaux Institute of onCology (BRIC), Bordeaux, France
9 shared publications - Violaine Moreau
Univ. Bordeaux, INSERM, BRIC, U1312 Bordeaux France
9 shared publications Cyril Dourthe
Université de Bordeaux, CNRS, INSERM, TBM‐Core, US5, UAR 3427 Bordeaux France
8 shared publications
Latest Publications
- Open Access
- 17 July 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 8766
Glycerol metabolism triggers trypanosome differentiation into transmissible forms in mammalian tissue-like conditions
In the mammalian host, Trypanosoma brucei proliferates as slender bloodstream forms before undergoing quorum-sensing (QS)-dependent differentiation into non-dividing transmissible stumpy-QS forms, a process that both controls parasitaemia and enables transmission to the tsetse fly. However, this model does not explain how transmission occurs in chronically infected patients and cattle, where parasite densities are often too low to trigger QS-mediated differentiation. We identify a relevant glycerol-dependent pathway driven by adipocyte-derived glycerol that offers an explanation for this transmission paradox. We show that, at low parasite density, and with physiological levels of glycerol (0.2 mM) and glucose (4 mM) mimicking adipose and hypodermal interstitial fluids, glycerol promotes the emergence of novel proliferative forms that we termed, slender-Glyc forms. These cells are transmissible, unlike the slender forms, since they ( i ) differentiate in vitro into procyclic forms, which appear in the midgut of the infected flies, and ( ii ) establish infections in the fly. In addition, at high parasite density, tissular amounts of glycerol extends the lifespan of stumpy-QS forms (named stumpy-QS/Glyc), increasing transmission chances for tissue parasites, especially in the skin. Altogether, our findings suggest that local metabolic conditions, either on their own or in combination with parasite density, can drive transmission capacity.
- 17 July 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 8766
Open AccessGlycerol metabolism triggers trypanosome differentiation into transmissible forms in mammalian tissue-like conditions
In the mammalian host, Trypanosoma brucei proliferates as slender bloodstream forms before undergoing quorum-sensing (QS)-dependent differentiation into non-dividing transmissible stumpy-QS forms, a process that both controls parasitaemia and enables transmission to the tsetse fly. However, this model does not explain how transmission occurs in chronically infected patients and cattle, where parasite densities are often too low to trigger QS-mediated differentiation. We identify a relevant glycerol-dependent pathway driven by adipocyte-derived glycerol that offers an explanation for this transmission paradox. We show that, at low parasite density, and with physiological levels of glycerol (0.2 mM) and glucose (4 mM) mimicking adipose and hypodermal interstitial fluids, glycerol promotes the emergence of novel proliferative forms that we termed, slender-Glyc forms. These cells are transmissible, unlike the slender forms, since they ( i ) differentiate in vitro into procyclic forms, which appear in the midgut of the infected flies, and ( ii ) establish infections in the fly. In addition, at high parasite density, tissular amounts of glycerol extends the lifespan of stumpy-QS forms (named stumpy-QS/Glyc), increasing transmission chances for tissue parasites, especially in the skin. Altogether, our findings suggest that local metabolic conditions, either on their own or in combination with parasite density, can drive transmission capacity.
- Open Access
- 30 June 2026
- Published by Elsevier in Fungal Biology
- Vol. 130 (6)
Contribution of the putative clathrin adaptor AP-1 subunit β to cell wall integrity and virulence factor secretion in the plant pathogen Botrytis cinerea
- 30 June 2026
- Published by Elsevier in Fungal Biology
- Vol. 130 (6)
Open AccessContribution of the putative clathrin adaptor AP-1 subunit β to cell wall integrity and virulence factor secretion in the plant pathogen Botrytis cinerea
- Open Access
- 14 April 2026
- Published by Wiley in Liver International
- Vol. 46 (5) , e70629
Proteomic Trajectories of Metabolic and Proteostatic Adaptation During Normothermic Liver Perfusion
Background: Normothermic machine perfusion (NMP) enables metabolic restoration and viability testing of liver grafts, but current viability criteria incompletely predict post‐transplant outcomes. The molecular basis of graft resilience or biliary vulnerability remains unclear. This study aimed to characterise tissue‐level proteomic trajectories during NMP and early reperfusion to identify molecular signatures associated with biliary complications after liver transplantation (LT). Methods: This prospective, single‐centre study was conducted at Rennes University Hospital. Twenty donation‐after‐brain‐death (DBD) livers underwent NMP; sixteen transplanted grafts with complete sequential biopsies and ≥ 6 months of follow‐up were analysed. Biopsies were collected after cold storage (B1), at the end of NMP (B2), and 1 h after graft reperfusion (B3). Proteins were quantified by high‐resolution LC–MS/MS and analysed with Proteome Discoverer 3.1/Chimerys. Pathway enrichment used Ingenuity Pathway Analysis to compare grafts with and without biliary complications. Results: Principal component analysis revealed distinct proteomic profiles between grafts with and without complications at all biopsy time points. During NMP (B2/B1), uncomplicated grafts showed glycolytic activation with attenuation of oxidative phosphorylation, whereas complicated grafts showed blunted glycolysis and mild OXPHOS upregulation. At reperfusion (B3/B2), complicated grafts displayed induction of translational and endoplasmic‐reticulum‐stress pathways, while resilient grafts maintained proteasome‐related protein turnover and enrichment of a hypoxia‐response signature driven by ELOC and proteasome subunits. Conclusions: Sequential tissue proteomics during NMP reveals divergent metabolic and proteostatic adaptations linked to biliary outcomes. Glycolytic activation with preserved protein turnover characterises resilient grafts, whereas translational and ER‐stress programmes predominate in complicated ones. These insights may refine viability assessment beyond biochemical criteria.
- 14 April 2026
- Published by Wiley in Liver International
- Vol. 46 (5) , e70629
Open AccessProteomic Trajectories of Metabolic and Proteostatic Adaptation During Normothermic Liver Perfusion
Background: Normothermic machine perfusion (NMP) enables metabolic restoration and viability testing of liver grafts, but current viability criteria incompletely predict post‐transplant outcomes. The molecular basis of graft resilience or biliary vulnerability remains unclear. This study aimed to characterise tissue‐level proteomic trajectories during NMP and early reperfusion to identify molecular signatures associated with biliary complications after liver transplantation (LT). Methods: This prospective, single‐centre study was conducted at Rennes University Hospital. Twenty donation‐after‐brain‐death (DBD) livers underwent NMP; sixteen transplanted grafts with complete sequential biopsies and ≥ 6 months of follow‐up were analysed. Biopsies were collected after cold storage (B1), at the end of NMP (B2), and 1 h after graft reperfusion (B3). Proteins were quantified by high‐resolution LC–MS/MS and analysed with Proteome Discoverer 3.1/Chimerys. Pathway enrichment used Ingenuity Pathway Analysis to compare grafts with and without biliary complications. Results: Principal component analysis revealed distinct proteomic profiles between grafts with and without complications at all biopsy time points. During NMP (B2/B1), uncomplicated grafts showed glycolytic activation with attenuation of oxidative phosphorylation, whereas complicated grafts showed blunted glycolysis and mild OXPHOS upregulation. At reperfusion (B3/B2), complicated grafts displayed induction of translational and endoplasmic‐reticulum‐stress pathways, while resilient grafts maintained proteasome‐related protein turnover and enrichment of a hypoxia‐response signature driven by ELOC and proteasome subunits. Conclusions: Sequential tissue proteomics during NMP reveals divergent metabolic and proteostatic adaptations linked to biliary outcomes. Glycolytic activation with preserved protein turnover characterises resilient grafts, whereas translational and ER‐stress programmes predominate in complicated ones. These insights may refine viability assessment beyond biochemical criteria.
- Open Access
- 17 March 2026
- Published by Springer Nature in Clinical Proteomics
- Vol. 23 (1)
Quantitative enrichment of amyloid precursors refines mass spectrometry-based amyloidosis diagnosis
Amyloidosis typing is crucial to determine the best therapeutic strategy for patients. Since conventional histological techniques often fail, the identific
- 17 March 2026
- Published by Springer Nature in Clinical Proteomics
- Vol. 23 (1)
Open AccessQuantitative enrichment of amyloid precursors refines mass spectrometry-based amyloidosis diagnosis
Amyloidosis typing is crucial to determine the best therapeutic strategy for patients. Since conventional histological techniques often fail, the identific
- Open Access
- 23 February 2026
- Published by Springer Nature in Molecular Cancer
- Vol. 25 (1)
EZH2 is a key prognostic marker and therapeutic target in aggressive and proliferative hepatoblastoma
Background: EZH2 is a histone methyltransferase and a key component of polycomb repressive complex 2 (PRC2). It plays a critical role in genome remodeling, gene regulation and acts through PRC2-dependent and independent mechanisms, which comprise methylation of histone and non-histone substrates, and transcriptional activation through different transcriptional complexes. EZH2 is involved in many cancers, but its role in hepatoblastoma is poorly understood. Methods: Potential correlation between EZH2 mRNA expression and clinical parameters was analyzed by computational and histological approaches using seven published transcriptomic datasets and tissue samples from patients with hepatoblastoma. EZH2 molecular function was deciphered using molecular approaches, gain- and loss-of-function genetic tools, proteomics, immunohistochemistry, pharmacological drugs, 2D cell- and spheroid-based assays, and four different animal models. Results: Our data show that EZH2 mRNA expression correlated with poor prognostic markers such as tumor proliferation, and patients’ death and shorter survival. EZH2 protein potentiated hepatoblastoma cell proliferation, migration, survival and cisplatin resistance through its histone methyltransferase activity by repressing DUSP5 , and transcriptionally inducing DUSP9 and HMGCR . In vivo EZH2 sustained tumor cell proliferation, and tumor development and angiogenesis. The EZH2 inhibitor GSK126 synergized with HMG-CoA reductase inhibitor statins to eradicate hepatoblastoma cells in vitro and block tumor development in mice. This combination was also very effective on various hepatoblastoma and non-hepatoblastoma tumor cell lines. Conclusion: Collectively, our data showed that the protein EZH2 promotes hepatoblastoma development, partly through its histone methyltransferase activity, by differentially modulating the expression of DUSP5 , DUSP9 and HMGCR genes and by supporting the MAPK/ERK pathway in hepatoblastoma cells already displaying high Wnt signal activity. EZH2 inhibitors triggered lipid synthesis in hepatoblastoma cells and synergized with cholesterol-lowering statins to block hepatoblastoma development in vitro and in vivo. Therefore, we demonstrate the key role of EZH2 in proliferative hepatoblastoma and the therapeutic benefit of combining EZH2 inhibitor and statin to treat patients with cancer.
- 23 February 2026
- Published by Springer Nature in Molecular Cancer
- Vol. 25 (1)
Open AccessEZH2 is a key prognostic marker and therapeutic target in aggressive and proliferative hepatoblastoma
Background: EZH2 is a histone methyltransferase and a key component of polycomb repressive complex 2 (PRC2). It plays a critical role in genome remodeling, gene regulation and acts through PRC2-dependent and independent mechanisms, which comprise methylation of histone and non-histone substrates, and transcriptional activation through different transcriptional complexes. EZH2 is involved in many cancers, but its role in hepatoblastoma is poorly understood. Methods: Potential correlation between EZH2 mRNA expression and clinical parameters was analyzed by computational and histological approaches using seven published transcriptomic datasets and tissue samples from patients with hepatoblastoma. EZH2 molecular function was deciphered using molecular approaches, gain- and loss-of-function genetic tools, proteomics, immunohistochemistry, pharmacological drugs, 2D cell- and spheroid-based assays, and four different animal models. Results: Our data show that EZH2 mRNA expression correlated with poor prognostic markers such as tumor proliferation, and patients’ death and shorter survival. EZH2 protein potentiated hepatoblastoma cell proliferation, migration, survival and cisplatin resistance through its histone methyltransferase activity by repressing DUSP5 , and transcriptionally inducing DUSP9 and HMGCR . In vivo EZH2 sustained tumor cell proliferation, and tumor development and angiogenesis. The EZH2 inhibitor GSK126 synergized with HMG-CoA reductase inhibitor statins to eradicate hepatoblastoma cells in vitro and block tumor development in mice. This combination was also very effective on various hepatoblastoma and non-hepatoblastoma tumor cell lines. Conclusion: Collectively, our data showed that the protein EZH2 promotes hepatoblastoma development, partly through its histone methyltransferase activity, by differentially modulating the expression of DUSP5 , DUSP9 and HMGCR genes and by supporting the MAPK/ERK pathway in hepatoblastoma cells already displaying high Wnt signal activity. EZH2 inhibitors triggered lipid synthesis in hepatoblastoma cells and synergized with cholesterol-lowering statins to block hepatoblastoma development in vitro and in vivo. Therefore, we demonstrate the key role of EZH2 in proliferative hepatoblastoma and the therapeutic benefit of combining EZH2 inhibitor and statin to treat patients with cancer.
- Open Access
- 14 November 2025
- Published by Springer Nature in Research Square
Quantitative enrichment of amyloid precursors refines mass spectrometry-based amyloidosis diagnosis
Introduction Amyloidosis typing is crucial to determine the best therapeutic strategy for patients. Since conventional histological techniques often fail, the identification of amyloid precursors by mass spectrometry became the new standard. However, without quantification, selecting the amyloid precursor from proteins that may be ubiquitous under non-pathological conditions may be equivocal. Therefore, we quantified protein enrichment in amyloid deposits to improve amyloidosis typing. Methods Protein enrichment was measured by extracted ion chromatogram-based label free quantification by comparing a microdissected amyloid area with a non-amyloid area. We assessed the discrimination ability of candidate precursors with this approach compared to the two practiced identification methods. Results As a proof-of-concept, we selected 9 cases including the most common amyloidosis subtypes, 6 typed by immunohistochemistry and 3 inconclusive by immunohistochemistry. Proteins associated with amyloid deposits were identified in all samples, confirming the pathology. Where the routine clinical mass spectrometric identification techniques allowed unambiguous conclusions for 3 of 9 cases, quantification of the enrichment ratio in amyloid deposits allowed unambiguous precursor selection in all cases. Conclusion Quantification of precursor enrichment in amyloid deposits is a promising optimization for amyloidosis typing. Incorporated into routine clinical processes, it will improve patient care in difficult diagnostic situations.
- 14 November 2025
- Published by Springer Nature in Research Square
Open AccessQuantitative enrichment of amyloid precursors refines mass spectrometry-based amyloidosis diagnosis
Introduction Amyloidosis typing is crucial to determine the best therapeutic strategy for patients. Since conventional histological techniques often fail, the identification of amyloid precursors by mass spectrometry became the new standard. However, without quantification, selecting the amyloid precursor from proteins that may be ubiquitous under non-pathological conditions may be equivocal. Therefore, we quantified protein enrichment in amyloid deposits to improve amyloidosis typing. Methods Protein enrichment was measured by extracted ion chromatogram-based label free quantification by comparing a microdissected amyloid area with a non-amyloid area. We assessed the discrimination ability of candidate precursors with this approach compared to the two practiced identification methods. Results As a proof-of-concept, we selected 9 cases including the most common amyloidosis subtypes, 6 typed by immunohistochemistry and 3 inconclusive by immunohistochemistry. Proteins associated with amyloid deposits were identified in all samples, confirming the pathology. Where the routine clinical mass spectrometric identification techniques allowed unambiguous conclusions for 3 of 9 cases, quantification of the enrichment ratio in amyloid deposits allowed unambiguous precursor selection in all cases. Conclusion Quantification of precursor enrichment in amyloid deposits is a promising optimization for amyloidosis typing. Incorporated into routine clinical processes, it will improve patient care in difficult diagnostic situations.
- Open Access
p190A/ ARHGAP35 and p190B/ ARHGAP5 proteins in endometrial cancer, a novel cancer-relevant paralog interplay
Endometrial cancer is one of the main gynecological malignancies worldwide, with an estimated 320, 000 new cases annually. Several studies highlight ARHGAP35 as a significantly mutated gene in these tumors. It encodes for the protein p190RhoGAP-A (p190A), which is a major regulator of the small GTPase family of proteins. ARHGAP5 is a paralog of ARHGAP35 that encodes the protein p190RhoGAP-B (p190B). By analyzing human endometrial cancer samples, we found a co-occurrence of mutations in ARHGAP35 and ARHGAP5 genes and we reported that both are less expressed at the mRNA level in tumoral samples compared to healthy tissues. We were interested in understanding the impact of p190A/B under-expression in endometrial cancer and the relationship between the two paralogs. To do so, we have used CRISPR/Cas9 technology to generate HEC-1-A knockout cells for p190A and p190B. We showed that removal of each paralog led to a similar actin remodeling phenotype with the formation of Cross-Linked Actin Networks (CLANs), dependent on the Rho/ROCK pathway. Moreover, proteomic analysis of p190A and p190B knockout cells highlighted similar affected cell functions. Finally, our study demonstrates a synthetic lethality between p190A and p190B where removal of both paralogs is deleterious in endometrial cancer cells, unveiling a potential actionable vulnerability.
Open Accessp190A/ ARHGAP35 and p190B/ ARHGAP5 proteins in endometrial cancer, a novel cancer-relevant paralog interplay
Endometrial cancer is one of the main gynecological malignancies worldwide, with an estimated 320, 000 new cases annually. Several studies highlight ARHGAP35 as a significantly mutated gene in these tumors. It encodes for the protein p190RhoGAP-A (p190A), which is a major regulator of the small GTPase family of proteins. ARHGAP5 is a paralog of ARHGAP35 that encodes the protein p190RhoGAP-B (p190B). By analyzing human endometrial cancer samples, we found a co-occurrence of mutations in ARHGAP35 and ARHGAP5 genes and we reported that both are less expressed at the mRNA level in tumoral samples compared to healthy tissues. We were interested in understanding the impact of p190A/B under-expression in endometrial cancer and the relationship between the two paralogs. To do so, we have used CRISPR/Cas9 technology to generate HEC-1-A knockout cells for p190A and p190B. We showed that removal of each paralog led to a similar actin remodeling phenotype with the formation of Cross-Linked Actin Networks (CLANs), dependent on the Rho/ROCK pathway. Moreover, proteomic analysis of p190A and p190B knockout cells highlighted similar affected cell functions. Finally, our study demonstrates a synthetic lethality between p190A and p190B where removal of both paralogs is deleterious in endometrial cancer cells, unveiling a potential actionable vulnerability.
- Open Access
- 8 October 2025
- Published by American Chemical Society (ACS) in ChemRxiv
A chemical proteomics method to quantify Cysteine S-acylation
S-acylation, often referred to as S-palmitoylation, is a reversible and dynamic post-translational modification which corresponds to the addition of a long-chain fatty acid to cysteine (Cys) residues. Established mass spectrometry-based chemoproteomics methods have improved our understanding of the S-acylation proteome, notably by identifying hundreds of S-acylated proteins, sometimes with the modified Cys. However, the precise quantification of S-acylation levels for each Cys within a single sample remains challenging at the proteome level. Quantification of S-acylation levels is critical to further our understanding of protein S-acylation in cellular function and its role in health and diseases. We report here the development of an S-acylation quantification workflow, based on the sequential labeling of free Cys and S-acylated Cys with isotopic labeling reagents. The workflow was extensively optimized, notably by comparing the number of sites identified with two alkyne-tagged Cys-reactive isotopic probes and four azido-tagged biotin-based capture reagents. By integrating this enhanced workflow with high-field asymmetric waveform ion mobility spectrometry (FAIMS) on LC-MS/MS instruments for the separation of labeled peptides, over 17,000 unique Cys could be quantified in biological samples. Applying the S-acylation quantification workflow to cellular proteomes enabled quantification of S-acylation levels in the HeLa proteome and revealed dynamic changes in response to autophagy induction.
- 8 October 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessA chemical proteomics method to quantify Cysteine S-acylation
S-acylation, often referred to as S-palmitoylation, is a reversible and dynamic post-translational modification which corresponds to the addition of a long-chain fatty acid to cysteine (Cys) residues. Established mass spectrometry-based chemoproteomics methods have improved our understanding of the S-acylation proteome, notably by identifying hundreds of S-acylated proteins, sometimes with the modified Cys. However, the precise quantification of S-acylation levels for each Cys within a single sample remains challenging at the proteome level. Quantification of S-acylation levels is critical to further our understanding of protein S-acylation in cellular function and its role in health and diseases. We report here the development of an S-acylation quantification workflow, based on the sequential labeling of free Cys and S-acylated Cys with isotopic labeling reagents. The workflow was extensively optimized, notably by comparing the number of sites identified with two alkyne-tagged Cys-reactive isotopic probes and four azido-tagged biotin-based capture reagents. By integrating this enhanced workflow with high-field asymmetric waveform ion mobility spectrometry (FAIMS) on LC-MS/MS instruments for the separation of labeled peptides, over 17,000 unique Cys could be quantified in biological samples. Applying the S-acylation quantification workflow to cellular proteomes enabled quantification of S-acylation levels in the HeLa proteome and revealed dynamic changes in response to autophagy induction.
- Open Access
- 25 August 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-26
The HDAC inhibitor romidepsin renders liver cancer vulnerable to RTK targeting and immunologically active
Histone deacetylases (HDACs) are epigenetic regulators frequently altered in cancer. Here we report that overexpression of HDAC1/2 occurs in Hepatocellular Carcinoma (HCC) patients, correlating with poor prognosis. We show that romidepsin, a class-I HDAC inhibitor, elicits a combinatorial perturbation of distinct molecular processes in HCC cells, altering lipid composition, mitotic spindle machinery, and levels of cell cycle/survival signals. Collectively, these alterations lead HCC cells to a vulnerable state, conferring dependency to receptor tyrosine kinase (RTK) signalling support. The cytostatic effects of romidepsin alone is converted into cytotoxicity by the RTK inhibitor cabozantinib in HCC models. We document that romidepsin+cabozantibib confers an immune-stimulatory profile in Alb-R26Met mouse models, with direct effects on primary human dendritic cell maturation in vitro. Our findings put forward the intricate crosstalk between epigenetics, metabolism, and immune response in cancer. The broad action of romidepsin on distinct cellular functions highlights its therapeutic potential for HCC treatment.
- 25 August 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-26
Open AccessThe HDAC inhibitor romidepsin renders liver cancer vulnerable to RTK targeting and immunologically active
Histone deacetylases (HDACs) are epigenetic regulators frequently altered in cancer. Here we report that overexpression of HDAC1/2 occurs in Hepatocellular Carcinoma (HCC) patients, correlating with poor prognosis. We show that romidepsin, a class-I HDAC inhibitor, elicits a combinatorial perturbation of distinct molecular processes in HCC cells, altering lipid composition, mitotic spindle machinery, and levels of cell cycle/survival signals. Collectively, these alterations lead HCC cells to a vulnerable state, conferring dependency to receptor tyrosine kinase (RTK) signalling support. The cytostatic effects of romidepsin alone is converted into cytotoxicity by the RTK inhibitor cabozantinib in HCC models. We document that romidepsin+cabozantibib confers an immune-stimulatory profile in Alb-R26Met mouse models, with direct effects on primary human dendritic cell maturation in vitro. Our findings put forward the intricate crosstalk between epigenetics, metabolism, and immune response in cancer. The broad action of romidepsin on distinct cellular functions highlights its therapeutic potential for HCC treatment.
- Top Cited Papers
- 26 February 2025
- Published by Springer Nature in Nature
- Vol. 640 (8058) , 524-533
Macrophages recycle phagocytosed bacteria to fuel immunometabolic responses
Macrophages specialize in phagocytosis, a cellular process that eliminates extracellular matter, including microorganisms, through internalization and degradation1,2. Despite the critical role of phagocytosis during bacterial infection, the fate of phagocytosed microbial cargo and its impact on the host cell are poorly understood. In this study, we show that ingested bacteria constitute an alternative nutrient source that skews immunometabolic host responses. By tracing stable isotope-labelled bacteria, we found that phagolysosomal degradation of bacteria provides carbon atoms and amino acids that are recycled into various metabolic pathways, including glutathione and itaconate biosynthesis, and satisfies the bioenergetic needs of macrophages. Metabolic recycling of microbially derived nutrients is regulated by the nutrient-sensing mechanistic target of rapamycin complex C1 and is intricately tied to microbial viability. Dead bacteria, as opposed to live bacteria, are enriched in cyclic adenosine monophosphate, sustain the cellular adenosine monophosphate pool and subsequently activate adenosine monophosphate protein kinase to inhibit the mechanistic target of rapamycin complex C1. Consequently, killed bacteria strongly fuel metabolic recycling and support macrophage survival but elicit decreased reactive oxygen species production and reduced interleukin-1β secretion compared to viable bacteria. These results provide a new insight into the fate of engulfed microorganisms and highlight a microbial viability-associated metabolite that triggers host metabolic and immune responses. Our findings hold promise for shaping immunometabolic intervention for various immune-related pathologies.
- 26 February 2025
- Published by Springer Nature in Nature
- Vol. 640 (8058) , 524-533
Top Cited PapersMacrophages recycle phagocytosed bacteria to fuel immunometabolic responses
Macrophages specialize in phagocytosis, a cellular process that eliminates extracellular matter, including microorganisms, through internalization and degradation1,2. Despite the critical role of phagocytosis during bacterial infection, the fate of phagocytosed microbial cargo and its impact on the host cell are poorly understood. In this study, we show that ingested bacteria constitute an alternative nutrient source that skews immunometabolic host responses. By tracing stable isotope-labelled bacteria, we found that phagolysosomal degradation of bacteria provides carbon atoms and amino acids that are recycled into various metabolic pathways, including glutathione and itaconate biosynthesis, and satisfies the bioenergetic needs of macrophages. Metabolic recycling of microbially derived nutrients is regulated by the nutrient-sensing mechanistic target of rapamycin complex C1 and is intricately tied to microbial viability. Dead bacteria, as opposed to live bacteria, are enriched in cyclic adenosine monophosphate, sustain the cellular adenosine monophosphate pool and subsequently activate adenosine monophosphate protein kinase to inhibit the mechanistic target of rapamycin complex C1. Consequently, killed bacteria strongly fuel metabolic recycling and support macrophage survival but elicit decreased reactive oxygen species production and reduced interleukin-1β secretion compared to viable bacteria. These results provide a new insight into the fate of engulfed microorganisms and highlight a microbial viability-associated metabolite that triggers host metabolic and immune responses. Our findings hold promise for shaping immunometabolic intervention for various immune-related pathologies.